Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 7.47B | 8.01B | 9.15B | 8.34B | 6.95B |
Gross Profit | 5.42B | 6.11B | 7.04B | 6.25B | 5.13B |
EBITDA | 2.31B | 2.92B | 3.85B | 3.70B | 3.05B |
Net Income | 1.62B | 2.40B | 3.26B | 3.02B | 2.53B |
Balance Sheet | |||||
Total Assets | 18.05B | 17.73B | 17.75B | 15.81B | 12.70B |
Cash, Cash Equivalents and Short-Term Investments | 5.87B | 6.14B | 5.87B | 4.36B | 2.67B |
Total Debt | 860.74M | 1.30B | 1.81B | 1.71B | 600.16M |
Total Liabilities | 1.64B | 2.17B | 3.02B | 2.96B | 1.60B |
Stockholders Equity | 16.31B | 15.52B | 14.59B | 12.75B | 11.03B |
Cash Flow | |||||
Free Cash Flow | 812.64M | 2.18B | 3.03B | 2.31B | 2.35B |
Operating Cash Flow | 1.27B | 2.50B | 3.55B | 2.49B | 2.69B |
Investing Cash Flow | -615.10M | -442.28M | -1.18B | -1.52B | -353.82M |
Financing Cash Flow | -1.26B | -2.13B | -1.40B | -258.39M | -1.03B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $29.86B | 16.92 | 10.17% | 5.36% | -8.91% | -34.40% | |
55 Neutral | €4.86B | 18.25 | -49.50% | 1.91% | 13.92% | -4.82% | |
$3.64B | 9.10 | 19.62% | 4.91% | ― | ― | ||
$5.69B | 9.75 | 7.22% | 2.49% | ― | ― | ||
$4.21B | 12.02 | 14.56% | 0.56% | ― | ― | ||
€3.54B | 7.96 | 6.98% | ― | ― | |||
78 Outperform | HK$33.72B | 13.48 | 15.61% | 2.74% | 10.59% | 31.83% |
China Medical System Holdings Limited has announced the receipt of an eligibility-to-list letter from the Singapore Exchange Securities Trading Limited for a proposed secondary listing of its ordinary shares. This move, which does not involve the issuance of new shares, aims to expand the company’s market presence and trading opportunities, although it remains subject to certain conditions and regulatory compliance.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$12.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced its intention to pursue a secondary listing of its issued ordinary shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This strategic move is expected to enhance the company’s market presence and provide additional opportunities for investment, potentially impacting its operations and positioning within the industry.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$12.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced its intention to pursue a secondary listing of its ordinary shares on the Singapore Exchange Securities Trading Limited. This strategic move is aimed at enhancing the company’s presence in the Singapore market, increasing its global visibility, and facilitating international business expansion. Although the listing will not involve issuing new shares, it is expected to broaden the shareholder base and open additional fundraising channels in the future, thereby improving the company’s corporate image and liquidity of its securities.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited announced the successful passage of all proposed resolutions at its Annual General Meeting held on April 24, 2025. The resolutions, which included the adoption of financial statements, approval of a final dividend, and re-election of directors, were passed with overwhelming support, indicating strong shareholder confidence in the company’s strategic direction.
China Medical System Holdings has announced its proposal to spin off its subsidiary, Dermavon Holdings Limited, and list it separately on the Main Board of the Stock Exchange of Hong Kong. This move is expected to provide Dermavon with a new financing platform, improve its corporate image, and enhance its business profile, allowing it to independently raise funds and focus on its core business. The spin-off aims to incentivize employees, improve transparency, and potentially offer higher returns to shareholders.
China Medical System Holdings Limited has announced proposed amendments to its memorandum and articles of association, which include provisions for electronic proxy submissions, electronic voting, and the removal of manual signature requirements for transfer instruments. These changes aim to modernize the company’s operations and improve efficiency, subject to shareholder approval at the upcoming Annual General Meeting.